Get the Stockscreener App
12.49
4.00%
0.48
After Hours:
12.49
Replimune Group Inc stock is traded at $12.49, with a volume of 2.31M.
It is up +4.00% in the last 24 hours and up +11.22% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
See More
Previous Close:
$12.01
Open:
$11.78
24h Volume:
2.31M
Relative Volume:
2.76
Market Cap:
$961.18M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-4.2054
EPS:
-2.97
Net Cash Flow:
$-176.27M
1W Performance:
-0.48%
1M Performance:
+11.22%
6M Performance:
+58.70%
1Y Performance:
+67.43%
1-Day Range:
$11.43
$13.04
1-Week Range:
$11.19
$13.04
52-Week Range:
$4.92
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
12.49 | 961.18M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune Group (NASDAQ:REPL) Stock Price Up 8.2%Here's Why - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 6,759 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune CEO Sushil Patel sells $124,200 in company stock - Investing.com
Replimune CEO Sushil Patel sells $124,200 in company stock By Investing.com - Investing.com UK
Wellington Management Group LLP Decreases Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
BNP Paribas Financial Markets Buys 6,748 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 4.7%Here's Why - MarketBeat
When (REPL) Moves Investors should Listen - Stock Traders Daily
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones By Investing.com - Investing.com South Africa
Replimune's SWOT analysis: biotech's melanoma treatment stock nears key milestones - Investing.com India
Replimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in November - MarketBeat
Fmr LLC Sells 120,776 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Fmr LLC Has $6.87 Million Position in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Charles Schwab Investment Management Inc. Buys 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Jacobs Levy Equity Management Inc. Sells 44,153 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
The Manufacturers Life Insurance Company Increases Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Average PT from Analysts - MarketBeat
Intech Investment Management LLC Buys New Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Where are the Opportunities in (REPL) - Stock Traders Daily
Replimune Group, Inc. (NASDAQ:REPL) Holdings Reduced by Redmile Group LLC - MarketBeat
Parkman Healthcare Partners LLC Buys 238,747 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune stock target raised to $19 on BLA submission By Investing.com - Investing.com Canada
Baker BROS. Advisors LP Has $121.06 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Algert Global LLC - MarketBeat
Braidwell LP Acquires 2,057,460 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat
Replimune Group Announces Pricing of Public Offering - Defense World
Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch - Seeking Alpha
Replimune Group Amends Sales Agreement with Leerink Partners LLC - Defense World
Replimune reduces offering size in amended sales agreement - Investing.com
Replimune reduces offering size in amended sales agreement By Investing.com - Investing.com Australia
SEC Form 424B5 filed by Replimune Group Inc. - Quantisnow
Cancer firm Replimune readies $125 million offering - The Pharma Letter
REPLReplimune Group, Inc. Latest Stock News & Market Updates - StockTitan
Replimune announces $125 million public offering By Investing.com - Investing.com South Africa
Replimune's SWOT analysis: stock outlook as RP1 nears key milestones By Investing.com - Investing.com Canada
Replimune Announces Pricing of Upsized Public Offering - The Manila Times
Replimune Prices $140M Upsized Public Offering of Common Stock & Warrants | REPL Stock News - StockTitan
Replimune's SWOT analysis: stock outlook as RP1 nears key milestones - Investing.com
How to Take Advantage of moves in (REPL) - Stock Traders Daily
Replimune announces $125 million public offering - Investing.com India
Replimune Announces Proposed Public Offering - The Manila Times
Canadian Dollar/Japanese Yen (CADJPY) QuotePress Release - The Globe and Mail
Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World
Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright - Defense World
Replimune's stock surges 19% after-hours on FDA BLA submission - MSN
Replimune Group (NASDAQ:REPL) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
BMO Capital Markets Increases Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):